Frontlight ResearchEarly access
Pancreatic cancer trials in China
326 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 1/2Taking peoplePhase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
- Where
- Jinan
- Age
- 18 years to 75 years
- People
- 188
- Run by
- Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT06819215 - No phaseTaking peopleEarly-stage Detection of LIver, Biliary TRAct and PancReatic Cancers
- Where
- Hangzhou
- Age
- 40 years to 75 years
- People
- 1,608
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06139042 - Phase 2Not yet taking people in ChinaQL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC
- Where
- Beijing
- Age
- 18 years and over
- People
- 30
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06750861 - Phase 3Taking peopleAdjuvant Chemoradiotherapy Versus Chemotherapy for Pancreatic Cancer (ADJUPANC)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 770
- Run by
- Changhai Hospital
See details and how to joinNCT06427447 - Phase 2Taking peopleAlbumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer
- Where
- Beijing
- Age
- 18 years and over
- People
- 128
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06789679 - Phase 2Not yet taking people in ChinaNeoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 50
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT05562297 - Phase 1/2Taking peopleLiposomal Irinotecan + Oxaliplatin + Bevacizumab Versus Liposomal Irinotecan + 5-FU/LV
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 138
- Run by
- Dai, Guanghai
See details and how to joinNCT06782685 - Phase 1/2Taking peopleBortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 63
- Run by
- First Affiliated Hospital of Zhejiang University
See details and how to joinNCT06572813 - Phase 1/2Taking peoplemFOLFIRINOX Plus Anlotinib and Sintilimab for Advanced Pancreatic Cancer
- Where
- Fuzhou, Zhangzhou
- Age
- 18 years to 75 years
- People
- 29
- Run by
- Fujian Provincial Hospital
See details and how to joinNCT06761027 - Phase 2Not yet taking people in ChinaMetronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 43
- Run by
- Zhejiang University
See details and how to joinNCT06759090 - Phase 1/2Taking peopleSurufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer
- Where
- Beijing
- Age
- 18 years to 75 years
- People
- 90
- Run by
- Chinese PLA General Hospital
See details and how to joinNCT05218889 - No phaseNot yet taking people in ChinaValidation of Joint-AI in Diagnosing Pancreatic Solid Lesions
- Where
- Wuhan
- Age
- 18 years and over
- People
- 716
- Run by
- Huazhong University of Science and Technology
See details and how to joinNCT06753318 - Phase 2Taking peopleNALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC
- Where
- Beijing
- Age
- 18 years and over
- People
- 30
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT06405490 - Phase 2Taking peopleA Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer
- Where
- Beijing, Guangzhou, Hangzhou, Jinan, Shanghai, Wuhan
- Age
- 18 years to 75 years
- People
- 78
- Run by
- Akeso
See details and how to joinNCT05859750 - No phaseTaking peopleThe Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Pancreatic Cancer.
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Ruijin Hospital
See details and how to joinNCT06601010 - Phase 2Taking peopleStudy of Adjuvant Nimotuzumab Combined with Nab-paclitaxel+ Gemcitabine in EGFR-positive Pancreatic Cancer
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 57
- Run by
- Zhejiang Provincial People's Hospital
See details and how to joinNCT06722911 - Phase 2/3Taking peopleVitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 50
- Run by
- Fudan University
See details and how to joinNCT06598033 - Phase 2/3Taking peopleVitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer
- Where
- Shanghai
- Age
- 18 years to 80 years
- People
- 50
- Run by
- Fudan University
See details and how to joinNCT06601283 - No phaseEnrolling by invitationThe Differences of Complications Between LPD(Laparoscopic Pancreaticoduodenectomy) and OPD(Open Pancreaticoduodenectomy)
- Where
- Shanghai
- Age
- 19 years and over
- People
- 220
- Run by
- Zhijun Bao
See details and how to joinNCT06685939 - No phaseTaking peopleAI-Assisted Non-Contrast CT for Multi-Cancer Screening
- Where
- Shanghai
- Age
- 18 years and over
- People
- 1,000,000
- Run by
- Guo ShiWei
See details and how to joinNCT06632886 - Early phase 1Not yet taking people in ChinaTP53 R248Q TCR-T Cell Therapy for Advanced Solid Tumor
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 9
- Run by
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
See details and how to joinNCT06619886 - Phase 2Not yet taking people in ChinaAnlotinib Plus Benmelstobart and AG in First-line Treatment of Advanced Metastatic Pancreatic Cancer (ALTER-PA-001)
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 104
- Run by
- RenJi Hospital
See details and how to joinNCT06621095 - Phase 1Not yet taking people in ChinaA PARG Inhibitor DAT-2645 Monotherapy in Patients with Advanced/Metastatic Solid Tumors Harboring BRCA1/2 Loss of Function Alterations And/or Other Defects in the DDR Pathway
- Where
- Beijing, Beijjing
- Age
- 18 years and over
- People
- 112
- Run by
- Danatlas Pharmaceuticals Co., Ltd
See details and how to joinNCT06614751 - No phaseTaking peopleA Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
- Where
- Shanghai
- Age
- 40 years to 75 years
- People
- 276
- Run by
- Fudan University
See details and how to joinNCT06166147 - Phase 2Taking peopleA Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)
- Where
- Beijing
- Age
- 18 years and over
- People
- 90
- Run by
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
See details and how to joinNCT06505395